Cytokines (IFNs, TNF-α, IL-2 and IL-12) and animal models of cancer

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 1, 1999, Pages 51-61

  Burke, Frances ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Animal models; Cancer; Cytokines; IFNs; IL 12; IL 2; TNF

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EFLORNITHINE; FLUOROURACIL; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MITOMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; GENE TARGETING; GENE THERAPY; HEMATOLOGIC DISEASE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOGRAFT; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; STROMA CELL; TRANSGENE; TUMOR CELL; TUMOR GROWTH; XENOGRAFT;

EID: 0032908878     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (182)

1. Balkwill FR, Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw (1994) 5: 379-85.
2. Mattern J, Bak M, Hahn EW et al, Human tumor xenografts as model for drug testing. Cancer Metastasis Rev (1988) 7: 263-84.
3. Fiebig HH, Comparison of tumour responses in nude mice and in patients. In: Human Tumour Xenografts in Anticancer Drug Development (ed B Winograd, HM Pinedo). Springer-Verlag, Berlin, 1988.
4. Fidler FJ, Rationale and methods for use of nude mice to study the biology and therapy of human cancer metastases. Cancer Metastasis Rev (1986) 5: 29-49.
5. Brinster RL, Chen HY, Messing A et al, Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 37: 367-79.
6. Thomas H, Balkwill FR, Oncogene transgenic mice as therapeutic models in cancer research. Eur J Cancer (1994) 4: 533-7.
7. Thomas H, Hanby AM, Smith RA et al, An inbred colony of oncogene transgenic mice - diversity of tumors and potential as a therapeutic model. Br J Cancer (1996) 73: 65-72.
8. Miller AR, McBride WH, Hunt K et al, Cytokine-mediated gene therapy for cancer. Ann Surg Oncol (1994) 1: 436-50.
9. Foa R, Cignetti A, Riera L et al, Cytokine gene therapy in oncology. Folia Biol Praha (1994) 40: 37-48.
10. Forni G, Cavallo F, Consalvo M et al, Molecular approaches to cancer immunotherapy. Cytokines Mol Ther (1995) 1: 225-48.
11. Golumbek PT, Azhari R, Jaffee EM et al, Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 53: 5841-4.
12. Kedar E, Braun E, Rutkowski Y et al, Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol (1994) 16: 115-24.
13. Kedar E, Palgi O, Golod G et al, Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother (1997) 20: 180-93.
14. Kedar E, Rutkowski Y, Braun E et al, Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother Emphasis Tumor Immunol (1994) 16: 47-59.
15. Anderson PM, Hanson DC, Hasz DE et al, Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. Cytokine (1994) 6: 92-101.
16. Balkwill FR, Goldstein L, Stebbing N, Differential action of six human interferons against two human carcinomas growing in nude mice. Int J Cancer (1985) 35: 613-17.
17. Balkwill F, Taylor Papadimitriou J, Fantes KH et al, Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur J Cancer (1980) 16: 569-73.
18. Balkwill FR, Moodie EM, Freedman V et al, Human interferon inhibits the growth of established human breast tumours in the nude mouse. Int J Cancer (1982) 30: 231-5.
19. Balkwill FR, Antitumour effects of interferons in animals. In: Interferon, Vol 4: In Vivo and Clinical Studies (ed N Finter) 23-45. Elsevier Science Publishers, Amsterdam, 1985.
20. Brosjo O, Bauer HCF, Brostrom L-A et al, Influence of human α-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res (1985) 45: 5598-602.
21. Brosjo O, Bauer HCF, Brostrom L-A et al, Growth inhibition of human osteosarcomas in nude mice by human interferon-α: significance of growth and tumour differentiation. Cancer Res (1987) 47: 258-62.
22. Hoffman RA, Langrehr JM, Dull KE et al, Nitric-oxide production by mouse sponge matrix allograft infiltrating cells - comparison with the rat-species. Transplantation (1993) 55: 591-6.
23. Forster S, Triffitt JT, Bauer HC et al, Interferon-inhibited human osteosarcoma xenografts induce host bone in nude mice. J Bone Miner Res (1988) 3: 199-202.
24. Sidky YA, Borden EC, Inhibition of angiogenesis by IFNs: effects on tumor and lymphocyte-induced vascular responses. Cancer Res (1987) 47: 5155-61.
25. Dinney CP, Bielenberg DR, Perrotte P et al, Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 58: 808-14.
26. Gresser I, Antitumor effects of interferon. Acta Oncol (1989) 28: 347-53.
27. Gresser I. How does interferon inhibit tumour growth? In: Interferon, Vol 6 (ed I Gresser) 93-126. Academic Press, London, 1985.
28. Dvorak HF, Gresser I, Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumours in mice. J Natl Cancer Inst (1989) 81: 497-502.
29. Gresser I, Belardelli F, Maury C et al, Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukaemia cells. V. Definition of optimal treatment regimens, Int J Cancer (1986) 38: 251-7.
30. Gresser I, Maury C, Bandu M et al, Importance of interferon alpha in the resistance of allogeneic C57b1/6 mice to the multiplication of Friend erythroleukemia cells in liver. Cancer (1990) 45: 364-71.
31. Kaido T, Gresser I, Maury C et al, Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN α/β therapy of Friend erythroleukemia visceral metastases. Int J Cancer (1993) 54: 475-81.
32. + T cells and IFN-α/β. Int J Cancer (1994) 57: 538-43.
33. Yasui H, Proietti E, Vignaux F et al, Inhibition of mouse α/β interferon of the multiplication of α/β interferon resistant Friend erythroleukemia cells co-cultured with mouse hepatocytes. Cancer Res (1990) 50: 3533-9.
34. Ramani P, Hart IR, Balkwill FR, The effect of interferon on experimental metastases in immunocompetent and immunodeficient mice. Int J Cancer (1986) 37: 563-8.
35. Ramani P, Balkwill FR, Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model, Int J Cancer (1989) 43: 140-6.
36. Kase S, Kubota T, Watanabe M et al, Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue. Anticancer Res (1994) 14: 1155-9.
37. Balkwill FR, Mowshowitz S, Seilman SS et al, Positive interactions between interferons and chemotherapy due to direct tumour action rather than effects on host drug metabolising enzymes. Cancer Res (1984) 44: 5249-55.
38. Marumo K, Oya M, Murai M, Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma, Int J Urol (1997) 4: 163-8.
39. Tanaka N, Kojima K, Muro M et al, Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft. Anticancer Res (1995) 15: 1949-52.
40. Balkwill FR, Lee A, Aldam G et al, Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res (1986) 46: 3990-3.
41. Bassukas ID, Hofmockel G, Maurer Schultze B, Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha. Anticancer Res (1994) 14: 237-45.
42. Savers TJ, Wiltrout TA, McCormick K et al, Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (renca) in vitro and in vivo. Cancer Res (1990) 50: 5414-20.
43. Tani K, Implantation of genetically manipulated fibroblasts into mice as a model of gene therapy - supplementations of human granulocyte colony-stimulating factor (hG-CSF) and interferon-alpha (IFN-alpha). Hum Cell (1991) 4: 25-32.
44. Ferrantini M, Giovarelli M, Modesti A et al, IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CDS+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol (1994) 153: 4604-15.
45. Ferrantini M, Proietti E, Santodonato L et al, A1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res (1993) 53: 1107-12.
46. Balkwill FR, Griffin DB, Lee AE, Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo. Eur J Cancer Clin Oncol (1989) 25: 1481-6.
47. Balkwill FR, Stevens MH, Griffin DB et al, Interferon gamma regulates HLA-D expression on solid tumors in vivo. Eur J Cancer Clin Oncol (1987) 23: 101-6.
48. Balkwill FR, Ward BG, Moodie E et al, Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res (1987) 47: 4755-8.
49. Malik STA, Knowles RG, East N et al, Antitumour activity of gamma interferon in ascitic and solid tumour models of human ovarian cancer. Cancer Res (1991) 51: 6643-9.
50. Burke F, East N, Upton C et al, Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer (1997) 33: 1114-21.
51. An Z, Wang X, Astoul P et al, Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. Anticancer Res (1996) 16: 2545-51.
52. Giovarelli M, Cofano F, Vecchi A et al, Interferon-activated tumor inhibition in vivo. Small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int J Cancer (1986) 37: 141-8.
53. Kondo H, Tanaka N, Naomoto Y et al, Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice. Jpn J Cancer Res (1987) 78: 1258-65.
54. Ramani P, Balkwill FR, Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma. Int J Cancer (1987) 40: 830-4.
55. Kelly SA, Gschmeissner S, East N et al, Enhancement of metastatic potential by gamma-interferon. Cancer Res (1991) 51: 4020-7.
56. Lollini PL, Bosco MC, Cavallo F et al, Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 55: 320-9.
57. Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Therapeutics (1996) 69: 1-14.
58. Watanabe Y, Kuribayashi K, Miyatake S et al, Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA (1989) 86: 9456-60.
59. Porgador A, Bannerji R, Watanabe Y et al, Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma geneinserted tumor cells. J Immunol (1993) 150: 1458-70.
60. Restifo NP, Spiess PJ, Karp SE et al, A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med (1992) 175: 1423-31.
61. Gansbacher B, Bannerji R, Daniels B et al, Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res (1990) 50: 7820-5.
62. Teramura Y, Watanabe Y, Kan N et al, Interferon-gamma-producing tumor induces host tumor-specific T-cell responses. Jpn J Cancer Res (1993) 84: 689-96.
63. Esumi N, Hunt B, Itaya T et al, Reduced tumourigenicity of murine tumour cells secreting γ-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res (1991) 51: 1185-9.
64. Hiura M, Hashimura T, Watanabe Y et al, Induction of specific anti-tumour immunity by interferon-gamma gene-transferred murine bladder carcinoma MBT-2. Folia Biol Praha (1994) 40: 49-61.
65. Balkwill FR, Ward BG, Fiers W, Effects of tumour necrosis factor on human tumour xenografts in nude mice. Ciba Found Symp (1987) 131: 154-69.
66. Creasey AA, Reynolds MT, Laird W, Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res (1986) 46: 5687-90.
67. Nosoh Y, Toge T, Nishiyama M et al, Antitumor effects of recombinant human tumor necrosis factor against human tumor xenografts transplanted into nude mice. Jpn J Surg (1987) 17: 51-4.
68. Sohmura Y, Nakata K, Yoshida H et al, Recombinant human tumor necrosis factor - II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunopharmacol (1986) 8: 357-68.
69. Manetta A, Podczaski E, Zaino RJ et al, Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenograft in nude mice. Gynecol Oncol (1989) 34: 360-4.
70. Malik STA, Griffin DB, Fiers W et al, Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer (1989) 44: 918-25.
71. Malik S, The activity of TNF in experimental cancer models. In: Tumor Necrosis Factors (ed B Beutler). Raven Press, New York, 1992.
72. Carswell EA, Old LJ, Kassel RJ et al, An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA (1975) 72: 3666-70.
73. Manda T, Shimomura K, Mukumoto S et al, Recombinant human tumor necrosis factor alpha: evidence of an indirect mode of antitumor activity. Cancer Res (1987) 47: 3707-11.
74. Mule JJ, Asher A, McIntosh J et al, Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother (1988) 26: 202-8.
75. Tomazic VJ, Farha M, Loftus A et al, Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J Immunol (1988) 140: 4056-61.
76. Palladino MA Jr, Shalaby MR, Kramer SM et al, Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumorspecific immunity. J Immunol (1987) 138: 4023-32.
77. Havell EA, Fiers W, North RJ, The antitumor function of tumor necrosis factor (TNF). Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med (1988) 167: 1067-85.
78. Haranaka K, Satomi N, Sakurai A, Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer (1984) 34: 263-7.
79. al Attiyah R, Rosen H, Rook GA, A model for the investigation of factors influencing haemorrhagic necrosis mediated by tumour necrosis factor in tissue sites primed with mycobacterial antigen preparations. Clin Exp Immunol (1992) 88: 537-42.
80. Malik ST, Naylor MS, East N et al, Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer (1990) 26: 1031-4.
81. Nishiyama Y, Fuchimoto S, Orita K, Preventive and antiproliferative effects of tumor necrosis factor against experimental hepatic metastases of mouse Colon-26 tumor. Jpn J Cancer Res (1989) 80: 366-72.
82. Orosz P, Echtenacher B, Falk W et al, Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med (1993) 177: 1391-8.
83. Talmadge JE, Phillips H, Schindler J et al, Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res (1987) 47: 5725-32.
84. Baisch H, Otto U, Kloppel G, Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies. Cancer Res (1990) 50: 6389-95.
85. Winkelhake JL, Stampfl S, Zimmerman RJ, Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res (1987) 47: 3948-53.
86. McIntosh JK, Mule JJ, Krosnick JA et al, Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2 and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res (1989) 49: 1408-14.
87. Ohkura M, Fuchimoto S, Orita K, Antitumor effect of recombinant human interleukin-1β alone and in combination with natural human tumor necrosis factor-α. Jpn J Cancer Res (1990) 81: 1026-31.
88. Mule JJ, McIntosh JK, Jablons DM et al, Antitumor activity of recombinant interleukin 6 in mice. J Exp Med (1990) 171: 629-36.
89. de Kossodo S, Moore R, Gschmeissner S et al, Changes in endogenous cytokines, adhesion molecules and platelets during cytokine induced tumour necrosis. Br J Cancer (1995) 72: 1165-72.
90. Oliff A, Defeo Jones D, Boyer M et al, Tumors secreting human TNF/cachectin induce cachexia in mice. Cell (1987) 50: 555-63.
91. Blankenstein T, Qin ZH, Uberla K et al, Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med (1991) 173: 1047-52.
92. Teng MN, Park BH, Koeppen HK et al, Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA (1991) 88: 3535-9.
93. Asher AL, Mule JJ, Kasid A et al, Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 146: 3227-34.
94. Yannelli JR, Hyatt C, Johnson S et al, Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-α) or interleukin-2 (IL-2). J Immunol Meth (1993) 161: 77-90.
95. Cao G, Kuriyama S, Du P et al, Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology (1997) 112: 501-10.
96. Mizuno M, Yoshida J, Oyama H et al, Growth inhibition of glioma cells by liposome-mediated cell transfection with tumor necrosis factor-alpha gene - its enhancement by prior gamma-interferon treatment. Neurol Med Chir Tokyo (1992) 32: 873-6.
97. Rakhmilevich AL, Janssen K, Turner J et al, Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther (1997) 8: 1303-11.
98. Moore AS, Theilen GH, Newell AD et al, Preclinical study of sequential tumour necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Res (1991) 51: 233-8.
99. Papa MZ, Mule JJ, Rosenberg SA, Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. Cancer Res (1986) 46: 4973-8.
100. Ettinghausen SE, Rosenberg SA, The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Springer Semin Immunopathol (1986) 9: 51-71.
101. Paciotti GF, Tamarkin L, Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo. Anticancer Res (1988) 8: 1233-9.
102. Sacchi M, Snyderman CH, Heo DS et al, Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Cancer Res (1990) 50: 3113-8.
103. Sacchi M, Vitolo D, Sedlmayr P et al, Induction of tumor regression in experimental model of human head and neck cancer by human LAK cells and IL-2. Int J Cancer (1991) 47: 784-91.
104. Greenberg PD, Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol (1986) 136: 1917-22.
105. Mule JJ, Smith CA, Rosenberg SA, Interleukin 4 can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med (1987) 166: 792-7.
106. Foa R, Fierro MT, Raspadori D et al, Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogcncic and autologous LAK effectors. Blood (1990) 76: 1349-54.
107. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16: 216-29.
108. Lafreniere R, Rosenberg SA, Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res (1985) 45: 3735-41.
109. Rosenberg S, Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst (1985) 75: 595-603.
110. Hirabayashi H, Yasumura S, Lin WC et al, Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells. Arch Otolaryngol Head Neck Surg (1995) 121: 285-92.
111. Henney CS, Kuribayashi K, Kern DE et al, Interleukin-2 augments natural killer cell activity. Nature (1981) 291: 335-8.
112. Mule JJ, Shu S, Schwarz SL et al, Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225: 1487-9.
113. Rosenberg SA, Spiess P, Lafreniere R, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 233: 1318-21.
114. Schwarz RE, Vujanovic NL, Hiserodt JC, Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res (1989) 49: 1441-6.
115. Mule JJ, Shu S, Rosenberg SA, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol (1985) 135: 642-6.
116. Ettinghausen SE, Rosenberg SA, Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res (1986) 46: 2784-92.
117. Brunda MJ, Antitumour activity of interleukin-2 combined with other cytokines. In: Interleukin-2 (ed J Waxman, FR Balkwill) 106-21. London, Blackwell Scientific Publications, 1992.
118. Brunda MJ, Bellantoni D, Sulich V, In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer (1987) 40: 365-71.
119. Iigo M, Sakurai M, Tamura T et al, In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant Interferon, on various syngeneic murine tumors. Cancer Res (1988) 48: 260-4.
120. Truitt GA, Brunda MJ, Levitt D et al, The therapeutic activity in cancer of IL-2 in combination with other cytokines. Cancer Surv (1989) 8: 875-89.
121. Sakura Y, Ootsu K, Shino A, Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha AD: occurrence of large granular cells in the tumor. Jpn J Cancer Res (1989) 80: 895-903.
122. Kim B, Stein S, Warnaka P et al, Enhanced in vivo therapy of pulmonary metastases with interferon and interleukin-2. J Surg Res (1988) 45: 66-73.
123. Rosenberg SA, Schwarz SL, Spiess PJ, Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst (1988) 80: 1393-7.
124. Hornung RL, Back TC, Zaharko DS et al, Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. J Immunol (1988) 141: 3671-9.
125. Cameron RB, McIntosh JK, Rosenberg SA, Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha interferon in the treatment of established murine hepatic metastases. Cancer Res (1988) 48: 5810-17.
126. Huland E, Falk B, Hubner D et al, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors. J Cancer Res Clin Oncol (1995) 121: 285-90.
127. Silagi S, Dutkowski R, Schaefer A, Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma. Int J Cancer (1988) 41: 315-22.
128. Mao XW, Kettering JD, Gridley DS, Immunotherapy with low-dose interleukin-2 and interferon-gamma in a murine tumor model. J Interferon Cytokine Res (1995) 15: 1017-27.
129. Agah R, Malloy B, Sherrod A et al, Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res (1988) 48: 2245-8.
130. Dubinett SM, Kurnick JT, Kradin RL, Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma. Am J Respir Cell Mol Biol (1989) 1: 361-9.
131. Nishimura T, Ohta S, Sato N et al, Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int J Cancer (1987) 40: 255-61.
132. McIntosh JK, Mule JJ, Merino MJ et al, Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor alpha. Cancer Res (1988) 48: 4011-17.
133. Iigo M, Nishikata K, Hoshi A, Effect of recombinant interleukin-1 alpha, recombinant interleukin-2, recombinant interferon-beta, and recombinant tumor necrosis factor on subcutaneously implanted adenocarcinoma 755 and Lewis lung carcinoma. J Biol Response Mod (1990) 9: 426-30.
134. Leder GH, Oppenheim M, Rosenstein M et al, Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo. Z. Gastroenterol (1995) 33: 499-502.
135. Gansbacher B, Zier K, Daniels B et al, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med (1990) 172: 1217-24.
136. Fearon ER, Pardoll DM, Itaya T et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60: 397-403.
137. Gansbacher B, Zier K, Cronin K et al, Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood (1992) 80: 2817-25.
138. Bubenik J, Simova J, Jandlova T, Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett (1990) 23: 287-92.
139. Ley V, Langlade Demoyen P, Kourilsky P et al, Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol (1991) 21: 851-4.
140. Connor J, Bannerji R, Saito S et al, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med (1993) 177: 1127-34.
141. Foa R, Guarini A, Cignetti A et al, Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun (1994) 13: 65-75.
142. Parker GA, Crook T, Bain M et al, Epstein-Barr virus nuclear antigen (EBNA) 3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 13: 2541-9.
143. Russell SJ, Eccles SA, Flemming CL et al, Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer (1991) 47: 244-51.
144. Toloza EM, Hunt K, Swisher S et al, In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther (1996) 3: 11-17.
145. Rabinovitch A, Sorensen O, Suarezpinzon WL et al, Analysis of cytokine messenger-RNA expression in syngeneic islet grafts of NOD mice - interleukin-2 and interferon-gamma messenger-RNA expression correlate with graft-rejection and interleukin-10 with graft-survival. Diabetologia (1994) 37: 833-7.
146. Cordier L, Duffour MT, Sabourin JC et al, Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther (1995) 2: 16-21.
147. Click RP, Lichtor T, Kim TS et al, Fibroblasts genetically-engineered to secrete cytokines suppress tumor-growth and induce antitumor immunity to a murine glioma in-vivo. Neurosurgery (1995) 36: 548-55.
148. Huang H, Chen SH, Kosai K et al, Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther (1996) 3: 980-7.
149. Bubenik J, Simova J, Bubenikova D et al, Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J Cancer Res Clin Oncol (1995) 121: 39-43.
150. Tanaka K, Hayashi H, Hamada C et al, Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA (1986) 83: 8723-7.
151. Boyano MD, Garcia de Galdeano A, Smith-Zubiaga I et al, IL-2 treatment of B16F10 melanoma cells stimulates metastatic-colonization in the liver. Anticancer Res (1997) 17: 1135-41.
152. Abdel Wahab Z, Li WP, Osanto S et al, Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol (1994) 159: 26-39.
153. Miller AR, McBride WH, Dubinett SM et al, Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood (1993) 82: 3686-94.
154. Karp SE, Farber A, Salo JC et al, Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol (1993) 150: 896-908.
155. Cavallo F, Giovarelli M, Gulino A et al, Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 149: 3627-35.
156. Hiscox S, Jiang WG, Interleukin-12, an emerging antitumor cytokine. In Vivo (1997) 11: 125-32.
157. Brunda MJ, Luistro L, Rumennik L et al, Antitumor-activity of interleukin-12 in preclinical models. Cancer Chemother Pharmacol (1996) 38: S16-21.
158. Dias S, Thomas H, Balkwill F, Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer (1998) 75: 151-7.
159. Fujiwara H, Hamaoka T, Antitumor and antimetastatic effects of interleukin-12. Cancer Chermother Pharmacol (1996) 38: S22-6.
160. Brunda MJ, Luistro L, Warrier RR et al, Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 178: 1223-30.
161. Gately MK, Gubler U, Brunda MJ et al, Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Therapeutic Immunol (1994) 1: 187-96.
162. Mu J, Zou JP, Yamamoto N et al, Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res (1995) 55: 4404-8.
163. Brunda MJ, Luistro L, Hendrzak JA et al, Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol (1995) 17: 71-7.
164. Zou JP, Yamamoto N, Fujii T et al, Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol (1995) 7: 1135-45.
165. Nastala CL, Edington HD, McKinney TG et al, Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 153: 1697-706.
166. Brunda MJ, Gately MK, Interleukin-12: potential role in cancer therapy. Important Adv Oncol (1995) 3-18.
167. Dias S, Balkwill FR, Int J Cancer (1998) in press.
168. Majewski S, Marczak M, Szmurlo A et al, Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in-vivo. J Invest Dermatol (1996) 106: 1114-18.
169. Voest EE, Kenyon BB, Oreilly MS et al, Inhibition of angiogenesis in-vivo by interleukin-12. J Natl Cancer Inst (1995) 87: 581-6.
170. Angiolillo AL, Sgadari C, Tosato G, A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci (1996) 795: 158-67.
171. Wigginton JM, Komschlies KL, Back TC et al, Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal-carcinoma. J Natl Cancer Inst (1996) 88: 38-43.
172. Teicher BA, Ara G, Menon K et al, In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer (1996) 65: 80-4.
173. Tahara H, Zah H Jr, Storkus WJ et al, Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 54: 182-9.
174. Zitvogel L, Tahara H, Cai Q et al, Construction and characterization of retroviral vectors expressing biologically-active human interleukin-12. Hum Gene Ther (1994) 5: 1493-506.
175. Zitvogel L, Tahara H, Robbins PD et al, Cancer-immunotherapy of established tumors with IL-12 - effective delivery by genetically-engineered fibroblasts. J Immunol (1995) 155: 1393-403.
176. Chen L, Chen D, Block E et al, Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol (1997) 159: 351-9.
177. Tahara H, Lotze MT, Iwamoto Y et al, Antitumor effects of interleukin-12 (IL-12) - applications for the immunotherapy and genetherapy of cancer. Gene Ther (1995) 2: 96-106.
178. Rakhmilevich AL, Turner J, Ford MJ et al, Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA (1996) 93: 6291-6.
179. Pappo I, Tahara H, Robbins PD et al, Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res (1995) 58: 218-26.
180. Tan J, Newton CA, Djeu JY et al, Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res (1996) 56: 3399-403.
181. Cavallo F, Signorelli P, Giovarelli M et al, Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 89: 1049-58.
182. Burke F, de Kossodo S, Balkwill F, Cytokines and cancer. In: Cytokines in Health and Disease (ed D Ramick) 563-80. Marcel Dekker, New York, 1997.